INS and Hepatic steatosis: Since hepatic steatosis has been regarded as a driving force for insulin resistance and type 2 diabetes mellitus [4], the improved insulin sensitivity by TRIM21 could ameliorate hepatic glucose and lipid metabolic disorders by ubiquitination of FASN expression.